Hostname: page-component-848d4c4894-v5vhk Total loading time: 0 Render date: 2024-07-05T22:06:35.240Z Has data issue: false hasContentIssue false
  • English
  • Français

A comparison of the acute toxicities using moderate hypo-fractionated intensity-modulated radiation therapy or volumetric modulated arc therapy for the treatment of early-stage prostate cancer

Published online by Cambridge University Press:  11 June 2015

Craig A. Elith ,
Shane E. Dempsey  and
Helen M. Warren-Forward
Craig A. Elith*
Affiliation:
Department of Radiation Therapy, BC Cancer Agency, Surrey, BC, Canada School of Health Sciences, University of Newcastle, Newcastle, NSW, Australia
Shane E. Dempsey
Affiliation:
School of Health Sciences, University of Newcastle, Newcastle, NSW, Australia
Helen M. Warren-Forward
Affiliation:
School of Health Sciences, University of Newcastle, Newcastle, NSW, Australia
*
Correspondence to: Craig A. Elith, Department of Radiation Therapy, BC Cancer Agency, 13750 96th Avenue, Surrey, BC V3V 1Z2, Canada. Tel: + 1 604 930 4055; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Aim

This study compared the acute toxicities reported during radiotherapy treatment using either intensity-modulated radiation therapy (IMRT) or volumetric-modulated arc therapy (VMAT) to deliver a moderate hypo-fractionated treatment for early-stage prostate cancer.

Material and methods

Acute toxicities are routinely reported at the clinical site for all patients using the Common Terminology Criteria for Adverse Events. Toxicity assessment is performed on day 1 of treatment, then once weekly thereafter. The recorded toxicities of 40 cases treated with five-field IMRT, and 32 cases treated using VMAT were retrospectively compared. All cases were prescribed 73·68 Gy in 28 fractions. Eight symptoms were assessed; diarrhoea, proctitis, fatigue, pain, dermatitis, urinary frequency, urinary retention and urinary tract pain.

Results

In terms of the overall toxicity recorded, VMAT was shown to reduce the toxicities of dermatitis, fatigue, pain and urinary frequency (p<0·05). Using IMRT, grade 2 toxicities were reported for proctitis, pain, urinary frequency, urinary retention and urinary tract pain. Using VMAT, grade 2 toxicities were reported for urinary frequency and urinary retention.

Findings

The research reported here is one of the first publications to demonstrate that VMAT is associated with decreased toxicities compared with IMRT for the treatment of early-stage prostate cancer.

Keywords

IMRTprostateRapidArctoxicityVMAT
Type
Original Articles
Information
Journal of Radiotherapy in Practice , Volume 14 , Issue 3 , September 2015 , pp. 274 - 284
Check for updates
Copyright
© Cambridge University Press 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kopp, R W, Duff, M, Catalfamo, F, Shah, D, Rajecki, M, Ahmad, K. VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample. Med Dosim 2011; 36 (4): 365–372.CrossRefGoogle ScholarPubMed
2.Sze, H C K, Lee, M C H, Hung, W, Yau, T, Lee, A W M. RapidArc radiotherapy planning for prostate cancer: single-arc and double-arc techniques vs. intensity-modulated radiotherapy. Med Dosim 2012; 37 (1): 87–91.CrossRefGoogle ScholarPubMed
3.Otto, K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys 2008; 35 (1): 310–317.CrossRefGoogle Scholar
4.Varian Medical Systems Inc. Varian’s new RapidArc Radiotherapy Technology, 2010. http://www.varian.com/us/oncology/treatments/treatment_techniques/rapidarc/resources.html. Accessed September 23, 2010.Google Scholar
5.Davidson, M T, Blake, S J, Batchelar, D L, Cheung, P, Mah, K. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80 (5): 1550–1558.CrossRefGoogle ScholarPubMed
6.Elith, C A, Cao, F, Dempsey, S E, Findlay, N, Warren-Forward, H. A Retrospective planning analysis comparing Volumetric-Modulated Arc Therapy (VMAT) to Intensity-Modulated Radiation Therapy (IMRT) for radiotherapy treatment of prostate cancer. JMIRS 2013; 44 (2): 79–86.Google ScholarPubMed
7.Elith, C A, Dempsey, S E, Warren-Forward, H M. A retrospective planning analysis comparing Intensity Modulated Radiation Therapy (IMRT) to Volumetric Modulated Arc Therapy (VMAT) using two optimization algorithms for the treatment of early stage prostate cancer. Journal of Medical Radiation Sciences 2013; 60 (3): 84–92.CrossRefGoogle ScholarPubMed
8.McGarry, C K, McMahon, S J, Craft, D, O`Sullivan, J M, Prise, K M, Hounsell, A R. Inverse planned constant dose rate Volumetric Modulated Arc Therapy (VMAT) as an effective alternative to five-field Intensity Modulated Radiation Therapy (IMRT) for prostate. JRP 2014; 13 (1): 68–78.CrossRefGoogle Scholar
9.Rao, M, Yang, W, Chen, Fet al. Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: plan quality, delivery efficiency and accuracy. Med Phys 2010; 37 (3): 1350–1359.CrossRefGoogle ScholarPubMed
10.Riou, O, Regnault de la Mothe, P, Azria, D, Ailleres, N, Dubois, J B, Fenoglietto, P. Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer. J Appl Clin Med Phys 2013; 14 (4): 4094.CrossRefGoogle ScholarPubMed
11.Shaffer, R, Morris, W J, Moiseenko, Vet al. Volumetric modulated Arc therapy and conventional intensity-modulated radiotherapy for simultaneous maximal intraprostatic boost: a planning comparison study. Clin Oncol 2009; 21 (5): 401–407.CrossRefGoogle ScholarPubMed
12.Tsai, C L, Wu, J K, Chao, H L, Tsai, Y C, Cheng, J C. Treatment and dosimetric advantages between VMAT, IMRT, and helical tomotherapy in prostate cancer. Med Dosim 2011; 36 (3): 264–271.CrossRefGoogle ScholarPubMed
13.Yoo, S, Wu, Q J, Lee, W R, Yin, F F. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes. Int J Radiat Oncol Biol Phys 2010; 76 (3): 935–942.CrossRefGoogle ScholarPubMed
14.Jolly, D, Alahakone, D, Meyer, J. A RapidArc planning strategy for prostate with simultaneous integrated boost. J Appl Clin Med Phys 2011; 12 (1): 3320.CrossRefGoogle Scholar
15.Guckenberger, M, Richter, A, Krieger, T, Wilbert, J, Baier, K, Flentje, M. Is a single arc sufficient in volumetric-modulated arc therapy (VMAT) for complex-shaped target volumes? Radiother Oncol 2009; 93 (2): 259–265.CrossRefGoogle ScholarPubMed
16.Kjaer-Kristoffersen, F, Ohlhues, L, Medin, J, Korreman, S. RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncol 2009; 48 (2): 227–232.CrossRefGoogle ScholarPubMed
17.Myrehaug, S, Chan, G, Craig, Tet al. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82 (4): e657–e662.CrossRefGoogle ScholarPubMed
18.Ost, P, Speleers, B, De Meerleer, Get al. Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys 2011; 79 (3): 920–926.CrossRefGoogle Scholar
19.Palma, D, Vollans, E, James, Ket al. Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72 (4): 996–1001.CrossRefGoogle ScholarPubMed
20.Sale, C, Moloney, P. Dose comparisons for conformal, IMRT and VMAT prostate plans. J Med Imaging Radiat Oncol 2011; 55 (6): 611–621.CrossRefGoogle ScholarPubMed
21.Zhang, P, Happersett, L, Hunt, M, Jackson, A, Zelefsky, M, Mageras, G. Volumetric modulated arc therapy: planning and evaluation for prostate cancer cases. Int J Radiat Oncol Biol Phys 2010; 76 (5): 1456–1462.CrossRefGoogle ScholarPubMed
22.Dearnaley, D P, Sydes, M R, Graham, J Det al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8 (6): 475–487.CrossRefGoogle ScholarPubMed
23.Peeters, S T, Heemsbergen, W D, Koper, P Cet al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24 (13): 1990–1996.CrossRefGoogle ScholarPubMed
24.Pollack, A, Zagars, G K, Starkschall, Get al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53 (5): 1097–1105.CrossRefGoogle Scholar
25.Zietman, A L, DeSilvio, M L, Slater, J Det al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294 (10): 1233–1239.CrossRefGoogle ScholarPubMed
26.Pesce, G A, Clivio, A, Cozzi, Let al. Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy. Radiat Oncol 2010; 5: 54.CrossRefGoogle ScholarPubMed
27.Alongi, F, Fogliata, A, Navarria, Pet al. Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol 2012; 188 (11): 990–996.CrossRefGoogle ScholarPubMed
28.Alongi, F, Cozzi, L, Fogliata, Aet al. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Anticancer Res 2013; 33 (10): 4537–4543.Google ScholarPubMed
29.Weber, D C, Wang, H, Cozzi, Let al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. Radiat Oncol 2009; 4: 34.CrossRefGoogle ScholarPubMed
30.National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.0, 2013. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40. Accessed December 31, 2013.Google Scholar
31.Treutwein, M, Hipp, M, Koelbl, O, Dobler, B. Searching standard parameters for volumetric modulated arc therapy (VMAT) of prostate cancer. Radiat Oncol 2012; 7: 108.CrossRefGoogle ScholarPubMed